← Back to Search

Neuroimaging for Migraine

N/A

Waitlist Available

Led By Catherine Chong, PhD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Female only.

Ages 20-45 years.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is investigating whether WMH are more common in women with migraines, and if so, what characteristics they have.

Who is the study for?

This study is specifically for women aged 20-45 who have white matter hyperintensities (WMH) on their brain MRI, which can be related to conditions like migraines or small vessel disease.

What is being tested?

The trial is focused on using brain neuroimaging techniques to investigate the presence and characteristics of WMH in women suffering from migraines.

What are the potential side effects?

Since this trial involves non-invasive brain imaging, there are minimal side effects. Participants may experience discomfort from lying still during the MRI procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am female.

Select...

I am between 20 and 45 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

WMH imaging disease parameters

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: Small vessel ischemic (SVI) disease cohortExperimental Treatment1 Intervention

Women diagnosed with SVI disease and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.

Group II: Multiple sclerosis (MS) cohortExperimental Treatment1 Intervention

Women diagnosed with MS and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.

Group III: Migraine cohortExperimental Treatment1 Intervention

Women with migraine and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.

0 / 2Eligibility criteria met